title: Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents?
abstract: The percutaneous treatment of patients with obstructive atherosclerotic disease in degenerated coronary saphenous vein bypass grafts still remains one of the great challenges in interventional cardiology. In this review, we discuss the actual evidence-based knowledge for the percutaneous management of this lesion subset, focusing in particular on the devices that are actually considered the "gold standard" for this treatment: bare metal stents and distal protection devices. We also comment on the negative results of the randomized trials regarding the promising polytetrafluoroethylene-covered stent-grafts. We finally offer insights into the currently available evidence for the use of drug-eluting stents in saphenous vein grafts. These devices are potentially the principal promise for the long-term successful sealing of vein graft disease; however, clear and definitive data coming from controlled trials are requested.
authors.affiliation: The Department of Cardiology, AZ Middelheim, Antwerp, Belgium. paul.vermeersch@zna.be
authors.forename: Paul
authors.initials: P
authors.lastname: Vermeersch
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Agostoni
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D016503:Drug Delivery Systems; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D012501:Saphenous Vein / Q000473:pathology / Q000637:transplantation*; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus